Electroporation as a strategy to promote HtrA1 gene uptake and chemotherapy efficacy in a mouse model of mesothelioma.

Enrico P. Spugnini, Irene Cardillo, Maurizio Fanciulli, Stefania Crispi, Bruno Vincenzi, Mariarosaria Boccellino, Lucio Quagliuolo, Alfonso Baldi

Research output: Contribution to journalArticle

Abstract

There is not a consensus on the best therapeutic approach to mesothelioma and the prognosis is still dismal. We have recently demonstrated that HtrA1 is a potential therapeutic target in mesothelioma cells. In this manuscript we describe that electroporation in a mouse mesothelioma xenograft was able to facilitate the expression of exogenous HtrA1 injected intra-lesionally in the tumors and to increase the penetration in the neoplastic cells of cisplatin given intra-peritoneally. Indeed, HtrA1 over-expression caused a significant slowing down of tumor growth; moreover, cisplatin efficacy in reducing tumor mass was amplified by electroporation and this phenomenon was even more significant when combining the electroporation of cisplatin and HtrA1. Considering that a substantial number of mesothelioma patients develop early local recurrence, even with radical resection combined with aggressive chemo- and radiotherapy, this multi-modality approach could be very effective in improving local tumor control after surgery. The identification of effective combination coupled with the development of novel equipments and electrodes will be instrumental in planning the translation of these results to humans as per correct laboratory-clinical interface.

Original languageEnglish
Pages (from-to)974-981
Number of pages8
JournalFrontiers in Bioscience - Elite
Volume5
Publication statusPublished - 2013

Fingerprint

Electroporation
Chemotherapy
Mesothelioma
Tumors
Genes
Cisplatin
Drug Therapy
Neoplasms
Clinical laboratories
Radiotherapy
Heterografts
Surgery
Electrodes
Planning
Recurrence
Equipment and Supplies
Therapeutics
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Spugnini, E. P., Cardillo, I., Fanciulli, M., Crispi, S., Vincenzi, B., Boccellino, M., ... Baldi, A. (2013). Electroporation as a strategy to promote HtrA1 gene uptake and chemotherapy efficacy in a mouse model of mesothelioma. Frontiers in Bioscience - Elite, 5, 974-981.

Electroporation as a strategy to promote HtrA1 gene uptake and chemotherapy efficacy in a mouse model of mesothelioma. / Spugnini, Enrico P.; Cardillo, Irene; Fanciulli, Maurizio; Crispi, Stefania; Vincenzi, Bruno; Boccellino, Mariarosaria; Quagliuolo, Lucio; Baldi, Alfonso.

In: Frontiers in Bioscience - Elite, Vol. 5, 2013, p. 974-981.

Research output: Contribution to journalArticle

Spugnini, EP, Cardillo, I, Fanciulli, M, Crispi, S, Vincenzi, B, Boccellino, M, Quagliuolo, L & Baldi, A 2013, 'Electroporation as a strategy to promote HtrA1 gene uptake and chemotherapy efficacy in a mouse model of mesothelioma.', Frontiers in Bioscience - Elite, vol. 5, pp. 974-981.
Spugnini, Enrico P. ; Cardillo, Irene ; Fanciulli, Maurizio ; Crispi, Stefania ; Vincenzi, Bruno ; Boccellino, Mariarosaria ; Quagliuolo, Lucio ; Baldi, Alfonso. / Electroporation as a strategy to promote HtrA1 gene uptake and chemotherapy efficacy in a mouse model of mesothelioma. In: Frontiers in Bioscience - Elite. 2013 ; Vol. 5. pp. 974-981.
@article{400759e0b15749a09a1301d4d2306403,
title = "Electroporation as a strategy to promote HtrA1 gene uptake and chemotherapy efficacy in a mouse model of mesothelioma.",
abstract = "There is not a consensus on the best therapeutic approach to mesothelioma and the prognosis is still dismal. We have recently demonstrated that HtrA1 is a potential therapeutic target in mesothelioma cells. In this manuscript we describe that electroporation in a mouse mesothelioma xenograft was able to facilitate the expression of exogenous HtrA1 injected intra-lesionally in the tumors and to increase the penetration in the neoplastic cells of cisplatin given intra-peritoneally. Indeed, HtrA1 over-expression caused a significant slowing down of tumor growth; moreover, cisplatin efficacy in reducing tumor mass was amplified by electroporation and this phenomenon was even more significant when combining the electroporation of cisplatin and HtrA1. Considering that a substantial number of mesothelioma patients develop early local recurrence, even with radical resection combined with aggressive chemo- and radiotherapy, this multi-modality approach could be very effective in improving local tumor control after surgery. The identification of effective combination coupled with the development of novel equipments and electrodes will be instrumental in planning the translation of these results to humans as per correct laboratory-clinical interface.",
author = "Spugnini, {Enrico P.} and Irene Cardillo and Maurizio Fanciulli and Stefania Crispi and Bruno Vincenzi and Mariarosaria Boccellino and Lucio Quagliuolo and Alfonso Baldi",
year = "2013",
language = "English",
volume = "5",
pages = "974--981",
journal = "Frontiers in Bioscience - Elite",
issn = "1945-0494",
publisher = "Frontiers in Bioscience",

}

TY - JOUR

T1 - Electroporation as a strategy to promote HtrA1 gene uptake and chemotherapy efficacy in a mouse model of mesothelioma.

AU - Spugnini, Enrico P.

AU - Cardillo, Irene

AU - Fanciulli, Maurizio

AU - Crispi, Stefania

AU - Vincenzi, Bruno

AU - Boccellino, Mariarosaria

AU - Quagliuolo, Lucio

AU - Baldi, Alfonso

PY - 2013

Y1 - 2013

N2 - There is not a consensus on the best therapeutic approach to mesothelioma and the prognosis is still dismal. We have recently demonstrated that HtrA1 is a potential therapeutic target in mesothelioma cells. In this manuscript we describe that electroporation in a mouse mesothelioma xenograft was able to facilitate the expression of exogenous HtrA1 injected intra-lesionally in the tumors and to increase the penetration in the neoplastic cells of cisplatin given intra-peritoneally. Indeed, HtrA1 over-expression caused a significant slowing down of tumor growth; moreover, cisplatin efficacy in reducing tumor mass was amplified by electroporation and this phenomenon was even more significant when combining the electroporation of cisplatin and HtrA1. Considering that a substantial number of mesothelioma patients develop early local recurrence, even with radical resection combined with aggressive chemo- and radiotherapy, this multi-modality approach could be very effective in improving local tumor control after surgery. The identification of effective combination coupled with the development of novel equipments and electrodes will be instrumental in planning the translation of these results to humans as per correct laboratory-clinical interface.

AB - There is not a consensus on the best therapeutic approach to mesothelioma and the prognosis is still dismal. We have recently demonstrated that HtrA1 is a potential therapeutic target in mesothelioma cells. In this manuscript we describe that electroporation in a mouse mesothelioma xenograft was able to facilitate the expression of exogenous HtrA1 injected intra-lesionally in the tumors and to increase the penetration in the neoplastic cells of cisplatin given intra-peritoneally. Indeed, HtrA1 over-expression caused a significant slowing down of tumor growth; moreover, cisplatin efficacy in reducing tumor mass was amplified by electroporation and this phenomenon was even more significant when combining the electroporation of cisplatin and HtrA1. Considering that a substantial number of mesothelioma patients develop early local recurrence, even with radical resection combined with aggressive chemo- and radiotherapy, this multi-modality approach could be very effective in improving local tumor control after surgery. The identification of effective combination coupled with the development of novel equipments and electrodes will be instrumental in planning the translation of these results to humans as per correct laboratory-clinical interface.

UR - http://www.scopus.com/inward/record.url?scp=84894383481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894383481&partnerID=8YFLogxK

M3 - Article

C2 - 23747913

VL - 5

SP - 974

EP - 981

JO - Frontiers in Bioscience - Elite

JF - Frontiers in Bioscience - Elite

SN - 1945-0494

ER -